Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Investor Presentation (June 2026)
21 slides from Island Pharmaceuticals's investor presentation, Jun 11, 2026
Slide 1: Combatting Urgent Viral Disease Threats
For personal use only COMBATTING URGENT VIRAL DISEASE THREATS Advancing Galidesivir as a multi-filovirus countermeasure under the FDA Animal Rule Dr David Foster, CEO & Managing Director | Mr Jason Carroll, Non-Executive Chairman June 2026 ASX: ILA
Slide 2: Disclaimer
Disclaimer For personal use only Important Information This disclaimer applies to this presentation and the information contained in it (Presentation). By reading this disclaimer you agree to be bound by it. The Presentation has been prepared by Island Pharmaceuticals Limited and all related bodies
Slide 3: Two Programs Targeting Infectious Diseases
For personal use only ISLAND PHARMACEUTICALS (ASX: ILA) TWO PROGRAMS TARGETING INFECTIOUS DISEASES Phase 2a/b PROTECT clinical trial in dengue Two, well advanced clinical stage programs complete FDA Animal Rule pathway actively Major market potential via both programs advancing through new USAMRIID
Slide 4: Company Overview
Company Overview Shares on issue¹: 295,916,682 For personal use only Substantial shareholders Price per share¹: $0.365 Dr William James Garner³ 15.50% Market capitalisation¹: $108.1m Cash at bank (31 March 2026)²: $14.2m Jason Alan Carroll³ 11.92% Potential additional capital from vested options MWP
Slide 5: Company Overview
Company Overview For personal use only Two clinical stage assets – Galidesivir and ISLA-101 - both with Priority Review Voucher potential based on approval Galidesivir: ￭ Small molecule with broad antiviral activity against numerous high-priority threats ￭ Robust development history with over US$70m
Slide 6: The Filovirus Threat Landscape
The Filovirus Threat Landscape For personal use only AN URGENT AND GROWING GLOBAL SECURITY CHALLENGE Extremely high fatality rates: Marburg up to 88%, Ebola up to 90%, Sudan up to 47%, Bundibugyo 30–50% Limited BSL-4 pathogens: Bioterror relevance: Current situation: countermeasures: Require maximum
Slide 7: The Preparedness Gap
The Preparedness Gap For personal use only THERE ARE NO FILOVIRUS THERAPEUTICS CAPABLE OF CROSS-STRAIN PROTECTION Existing Ebola countermeasures No approved therapeutics for are strain-specific (Zaire only) Marburg, Bundibugyo or Sudan virus Outbreaks increasingly involve Stockpile lacks a broad-act
Slide 8: Why Galidesivir?
Why Galidesivir? For personal use only A BROAD-ACTING ANTIVIRAL WITH STRONG FILOVIRUS EFFICACY AND FDA-ALIGNED PATHWAY Demonstrated multi-filovirus activity IV and IM formulations with favorable (Marburg, Ebola, Sudan) safety profile Strong in vivo efficacy with delayed Manufacturing route improved
Slide 9: Galidesivir Competitive Advantage
Galidesivir Competitive Advantage For personal use only MRNA-LNP FEATURE GALIDESIVIR OBELDESIVIR REMDESIVIR MAFTIVIMAB MBP134 CHADOX1-BDBV RVSV-BDBV-GP BDBV BROADEST SPECTRUM ANTIVIRAL ACTIVITY (FILOVIRUSES AND OTHER FAMILIES) PEP AND TX FLEXIBILITY (IM/IV) ROOM TEMP STABLE SMALL MOLECULE PHASE 1 HU
Slide 10: Marburg NHP Survival
MARBURG NHP SURVIVAL For personal use only 94% survival in Marburg NHP Model with treatment initiated up to 48 hours post-infection This level of efficacy, with a clinically meaningful therapeutic window, is rare in filovirus models and directly supports Animal Rule advancement Island Pharmaceutical
Slide 11: Ebola NHP Survival
EBOLA NHP SURVIVAL For personal use only Robust efficacy in Ebola NHP model with delayed dosing Survival of rhesus non-human primates challenged with Ebola virus following intramuscular administration of 100 mg/kg BID loading dose followed by 25 mg/kg BID for 10 days. Percentage survival 100% surviv
Slide 12: FDA alignment significantly de-risks regulatory pathway
FDA alignment significantly de-risks regulatory pathway For personal use only Island has the potential to become to first Australian company to gain drug approval via the FDA’s Animal Rule FDA confirmed the Clear guidance provided FDA advised that CRADA secured with Animal Rule pathway on clinical p
Slide 13: An Established Regulatory Pathway
An Established Regulatory Pathway For personal use only 4~8 YEARS 4~6 YEARS 1 YEAR In vivo Basic Drug Experiment experiments Phase 1 Phase 2 Phase 3 NDA study design in vitro (animal clinical trials clinical trials clinical studies) trials In vivo Pivotal Basic Drug Experiment experiments efficacy A
Slide 14: Expanded CRADA with USAMRIID
Expanded CRADA with USAMRIID Agreement with US Army Medical Research Institute of Infectious Diseases and the Geneva Foundation For personal use only to secured 23 non-human primates and advance dose optimisation study USAMRIID is the US Amended CRADA Dose optimisation study Study to evaluate high A
Slide 15: NHP dose optimisation protocol
NHP dose optimisation protocol For personal use only GALDESIVIR DISEASE ADMINISTRATION DOSING BIOMARKER PK SPECIMEN STUDY GROUP # ANIMALS GALDESIVIR DOSE ENDPOINTS (HR POST VIRUS FREQUENCY SPECIMEN COLLECTION EXPOSURE) COLLECTION 0 MG/KG (VEHICLE 1 4 CONTROL - 30MIN 24 HOURS BID INFUSION) 15 MG/KG (
Slide 16: Recent appointments strengthen clinical development
Recent appointments strengthen clinical development Combining deep Galidesivir expertise with extensive US biodefence and procurement experience to accelerate development, funding and commercialisation opportunities For personal use only Mark Herzog – Senior Global Health Security Advisor Raymond Ta
Slide 17: Current Ebola outbreak highlights the opportunity
Current Ebola outbreak highlights the opportunity Emerging filovirus outbreaks continue to reinforce the importance of preparedness, rapid response capability and effective medical countermeasures For personal use only Governments continue to prioritise Active Ebola outbreak in East Africa: Limited
Slide 18: Supply chain optimised to meet pending demand
Supply chain optimised to meet pending demand Critical manufacturing and quality infrastructure being established to support FDA submission and future procurement opportunities For personal use only Manufacturing campaign commenced: • Agreement with PI Health Sciences for a 5kg GMP • GMP-grade Galid
Slide 19: Multiple commercialisation opportunities
Multiple commercialisation opportunities Galidesivir has the potential to fill multiple gaps in the US government’s biodefence stockpile For personal use only Non-human PRV Eligible for Animal Rule Strategic National Virus Cell culture data Animal data primate efficacy first indication Potential Sto
Slide 20: Animal Rule is a proven path for bioterror threat countermeasures
ANIMAL RULE IS A PROVEN PATH FOR BIOTERROR THREAT COUNTERMEASURES For personal use only Since 2012, the FDA’s Animal Rule approval has led to 8 bioterror countermeasures joining the US Strategic National Stockpile (SNS) In 7 out of 8 cases, these medical countermeasures continue to remain under SNS
Slide 21: Island Pharmaceuticals
For personal use only Island Pharmaceuticals ASX: ILA dfoster@islandpharmaceuticals.com islandpharmaceuticals.com @IslandPharma Island Pharmaceuticals
Island Pharmaceuticals — Investor Presentation (June 2026) on 6ix